The synthesis and antibacterial activity of novel 3-o-arylalkylbenzamide derivatives as FtsZ inhibitors

Letters in Drug Design and Discovery

Volumn 10, Issue 4, 2013, Pages 320-326

  Ma, Shutao ^a   Ma, Siti ^a   Wang, Rongmei ^b   Wang, Yuanze ^a   Cao, Jichao ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

3 O Arylalkyl groups; Antibacterial evaluation; Benzamide derivatives; FtsZ inhibitors; Resistant bacteria; Synthesis

Indexed keywords

3 (3 BROMOPROPOXY)BENZAMIDE; 3 (3 PHENOXYPROPOXY)BENZAMIDE; 3 (4 BROMOBUTOXY)BENZAMIDE; 3 (4 PHENOXYBUTOXY)BENZAMIDE; 3 [(2 ETHYLHEXYL)OXY]BENZAMIDE; 3 [(2 METHYLPROPYL)OXY]BENZAMIDE; 3 [(3 METHYLBUTYL)OXY]BENZAMIDE; 3 [3 (BENZO[D]THIAZOL 2 YLTHIO)PROPOXY]BENZAMIDE; 3 [4 (BENZO[D]THIAZOL 2 YLTHIO)BUTOXY]BENDAMIDE; 3 HYDROXYBENZAMIDE; 3 METHOXYBENZAMIDE; ANTIBIOTIC AGENT; BENZAMIDE DERIVATIVE; ETHYL 2 [3 (AMINOCARBONYL)PHENOXY]ACETATE; ETHYL 4 [3 (AMINOCARBONYL)PHENOXY]BUTYLATE; FTSZ PROTEIN; HETEROCYCLIC COMPOUND; METHYL GROUP; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL CELL; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STRUCTURE ACTIVITY RELATION;

EID: 84879756680     PISSN: 15701808     EISSN: 1875628X     Source Type: Journal    
DOI: 10.2174/1570180811310040005     Document Type: Article

References (22)

1. Hardy, K.J.; Hawkey, P.M.; Gao, F.; Oppenheim, B.A. Methicillin resistant Staphylococcus aureus in the critically ill. Brit. J. Anaesth., 2004, 92(1), 121-130.
2. Deurenberg, R.H.; Stobberingh, E.E. The molecular evolution of hospitaland community-associated methicillin-resistant Staphylo-coccus aureus. Curr. Mol. Med., 2009, 9(2), 100-115.
3. de Kraker, M.E.; Wolkewitz, M.; Davey, P.G.; Koller, W.; Berger, J.; Nagler, J.; Icket, C.; Kalenic, S.; Horvatic, J.; Seifert, H.; Kaasch, A.J.; Paniara, O.; Argyropoulou, A.; Bompola, M.; Smyth, E.; Skally, M.; Raglio, A.; Dumpis, U.; Kelmere, A.M.; Borg, M.; Xuereb, D.; Ghita, M.C.; Noble, M.; Kolman, J.; Grabljevec, S.; Turner, D.; Lansbury, L.; Grundmann, H. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob. Agents Chemother., 2011, 55(4), 1598-1605.
4. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Soci-ety of America. Clin. Infect. Dis., 2009, 48(1), 1-12.
5. Pascu, M.L. Hot topic progress in fighting the multidrug resistance of bacteria to treatment. Lett. Drug Des. Discov., 2011, 8(2), 100-100.
6. Projan, S.J. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol., 2003, 6(5), 427-430.
7. Mar, S.W.; Lin, M.N.; Chu, S.L.; Sakharkar, K.; Hock, T.T.; Sakharkar, R. Ethyl gallate as a combination drug can overcome resis-tance in MRSA. Lett. Drug Des. Discov., 2011, 8(1), 65-68.
8. Gould, I.M.; David, M.Z.; Esposito, S.; Garau, J.; Lina, G.; Mazzei, T.; Peters, G. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int. J. An-timicrob. Agents, 2012, 39(2), 96-104.
9. Harry, E.; Monahan, L.; Thompson, L. Bacterial cell division: the mechanism and its precision. Int. Rev. Cytol., 2006, 253, 27-94.
10. Errington, J.; Adams, D.W. Bacterial cell division: assembly, maintenance and disassembly of the Z ring. Nat. Rev. Microbiol., 2009, 7(9), 642-653.
11. Erickson, H.P.; Osawa, M.; Anderson, D.E. Reconstitution of contractile Fts Z rings in liposomes. Science, 2008, 320(5877), 792-794.
12. Margalit, D.N.; Romberg, L.; Mets, R.B.; Hebert, A.M.; Mitchison, T.J.; Kirschner, M.W.; Chaudhuri, D.R. Targeting cell division: small-molecule inhibitors of Fts Z GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(32), 11821-11826.
13. Ma, S.; Ma, S. The development of Fts Z inhibitors as potential antibacterial agents. Chem Med Chem 2012, 7(7), 1161-1172.
14. Ohashi, Y.; Chijiiwa, Y.; Suzuki, K.; Takahashi, K.; Nanamiya, H.; Sato, T.; Hosoya, Y.; Ochi, K.; Kawamura, F. The lethal effect of a benzamide derivative, 3-methoxybenzamide, can be suppressed by mutations within a cell division gene, Fts Z, in Bacillus subtilis. J. Bacteriol., 1999, 181(4), 1348-1351.
15. Perrone, R.; Berardi, F.; Colabufo, N. A.; Leopoldo, M.; Tortorella, V. N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3methoxybenzamide: a potent and selective dopamine D4 ligand. J. Med. Chem., 1998, 41(24), 4903-4909.
16. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today, 2004, 9(10), 430-431.
17. Haydon, D.J.; Stokes, N.R.; Ure, R.; Galbraith, G.; Bennett, J.M.; Brown, D.R.; Baker, P.J.; Barynin, V.V.; Rice, D.W.; Sedelnikova, S.E.; Heal, J.R.; Sheridan, J.M.; Aiwale, S.T.; Chauhan, P.K.; Srivastava, A.; Taneja, A.; Collins, I.; Errington, J.; Czaplewski, L.G. An inhibitor of Fts Z with potent and selective anti-staphylococcal activity. Science, 2008, 321(5896):1673-1675.
18. Andreu, J.M.; Schaffner-Barbero, C.; Huecas, S.; Alonso, D.; Lopez-Rodriguez, M.L.; Ruiz-Avila, L.B.; Núñez-Ramírez, R.; Llorca, O.; Martín-Galiano, A.J. The antibacterial cell division inhibitor PC190723 is an Fts Z polymer-stabilizing agent that induces filament assembly and condensation. J. Biol. Chem., 2010, 285(19), 14239-14246.
19. Czaplewski, L.G.; Collins, I.; Boyd, E.A.; Brown, D.; East, S.P.; Gardiner, M.; Fletcher, R.; Haydon, D.J.; Henstock, V.; Ingram, P.; Jones, C.; Noula, C.; Kennison, L.; Rockley, C.; Rose, V.; Thomaides-Brears, H.B.; Ure, R.; Whittaker, M.; Stokes, N.R. Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein Fts Z. Bioorg. Med. Chem. Lett., 2009, 19(2), 524-527.
20. Stokes, N.R.; Sievers, J.; Barker, S.; Bennett, J.M.; Brown, D.R.; Collins, I.; Errington, V.M.; Foulger, D.; Hall, M.; Halsey, R.; Johnson, H.; Rose, V.; Thomaides, H.B.; Haydon, D.J.; Czaplewski, L.G.; Errington, J. Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay. J. Biol. Chem., 2005, 280(48), 39709-39715.
21. Andrews, J.M. Determination of minimum inhibitory concentrations. Antimicrob. Chemother., 2001, 48(Suppl. 5), 5-16.
22. NCCLS. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically M7-A5, Vol. 20, National Committee on Clinical Laboratory Standards, Wayne, PA 2000, p. 2.